Role of vascular endothelial growth factor polymorphisms (-2578C > A, -460 T > C, -1154G > A, +405G > C and +936C > T) in endometriosis: a case–control study with Brazilians

Table 5 Haplotype distributions of VEGF p olymorphisms in cases and controls and their association with the risk of developing endometriosis

-2578C > A/ -460 T > C/ -1154G > A/ +405G > C *VEGF*haplotypes	Controls	All Cases	Pvalue^b	OR (95% CI)^c	DIE Cases	Pvalue^b	OR (95% IC)^d	Stages III-IV	Pvalue^b	OR (95% IC)^e
	(N = 112)	(N = 182)			(N = 151)			(N = 110)
					(N = 151)			N (%)
					N (%)
	No (%)	No (%)			N (%)
CTGG	42 (18.7)	85 (23.4)		1^a	69 (22.9)		1^a	55 (25.0)		1^a
CTGC	90 (40.1)	121 (33.2)	0.10	0.66 (0.42 – 1.05)	104 (34.4)	0.18	0.70 (0.44 – 1.13)	69 (31.3)	0.05	0.58 (0.35 – 0.97)
ACAG	36 (16.0)	96 (26.4)	0.38	1.32 (0.77 – 2.24)	78 (25.8)	0.40	1.32 (0.76 – 2.29)	58 (26.4)	0.58	1.23 (0.69 – 2.19)
ACGG	37 (16.5)	51 (14.0)	0.23	0.68 (0.39 – 1.19)	42 (13.9)	0.27	0.69 (0.38 – 1.24)	31 (14.1)	0.21	0.64 (0.34 – 1.19)
CCGG	15 (6.7)	11 (3.0)	0.03	0.36 (0.15 – 0.86)	9 (3.0)	0.05	0.37 (0.15 – 0.90)	7 (3.2)	0.05	0.35 (0.13 – 0.95)
ATGG	4 (2.0)	0 (0.0)	0.03	-	0 (0.0)	0.05	-	0 (0.0)	0.09	-

OR is odds ratio, CI is confidence interval. ^aReference Group; ^bChi-Square Test or Fisher’s exact test; ^cControls vs. Cases (All patients with endometriosis); ^dControls vs. Deeply infiltrating endometriosis patients (DIE); ^eControls vs. Moderate or severe endometriosis patients (stages III or IV).

ISSN: 1472-6874